Donate Help Contact The AHA Sign In Home
American Heart Association
Stroke
Search: search_blue_button Advanced Search
Stroke. 2004;35:2708-2711
Published online before print September 16, 2004, doi: 10.1161/01.STR.0000143319.73503.38
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
35/11_suppl_1/2708    most recent
01.STR.0000143319.73503.38v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Endres, M.
Right arrow Articles by Laufs, U.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Endres, M.
Right arrow Articles by Laufs, U.
Related Collections
Right arrow Acute coronary syndromes

(Stroke. 2004;35:2708.)
© 2004 American Heart Association, Inc.


Articles

Effects of Statins on Endothelium and Signaling Mechanisms

Matthias Endres, MD Ulrich Laufs, MD

From the Klinik und Poliklinik für Neurologie (M.E.), Charité, Humboldt-Universität Berlin, Germany; and the Klinik für Kardiologie (U.L.), Universität des Saarlandes, Homburg, Germany.

Correspondence to Dr Matthias Endres, Klinik und Poliklinik für Neurologie, Charité-Universitätsmedizin Berlin, Campus Mitte, Schumannstr 20/21, 10117 Berlin, Germany. E-mail Matthias.endres{at}charite.de

Endothelium dysfunction may result from increased production of reactive oxygen species and decreased availability of nitric oxide. Inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase (ie, statins) exert cholesterol-independent vasoprotective effects that are mediated, in part, through the inhibition of small G-proteins Rho and Rac. Rho negatively regulates endothelial nitric oxide synthase and Rac contributes to NAD(P)H-oxidase activation and superoxide production. Statins inhibit both Rho and Rac GTPase activity via inhibition of geranylgeranylation, which confers endothelial nitric oxide synthase upregulation and decreases superoxide production, respectively. Sudden discontinuation of statin therapy may have negative effects. Withdrawal of statin treatment leads to an overshoot activation of Rho and Rac with dramatic effects on nitric oxide bioavailability, NAD(P)H-oxidase activity, and superoxide production.


Key Words: acute care




This article has been cited by other articles:


Home page
J. Appl. Physiol.Home page
J. Andresen, N. I. Shafi, and R. M. Bryan Jr.
Endothelial influences on cerebrovascular tone
J Appl Physiol, January 1, 2006; 100(1): 318 - 327.
[Abstract] [Full Text] [PDF]